• Site selection process advancing for planned TACTI-002 Phase II trial which will include recruitment of up to 110 patients
• AIPAC Phase IIb recruitment reaches 155 patients or more than 68% of total patients and first Progression-Free Survival data remains on track for the second half of calendar 2019
• New Phase I trial in collaboration with Merck KGaA, Darmstadt, Germany and Pfizer Inc. to include recruitment of 12 patients in different solid tumors, as an extension to INSIGHT
• EOC Pharma doses first patient in Phase I clinical trial with efti in China
SYDNEY, AUSTRALIA – November 1, 2018 – Immutep Limited (ASX:IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, provides an operational update on the Company’s ongoing clinical and preclinical development of eftilagimod alpha (“efti” or “IMP321”) and IMP761, respectively, as well as the Company’s partnered clinical programs.
For further information please download PDF attached:
Download this document